GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little evidence of improving cardiorespiratory fitness, researchers say.

Everyone aspires to live a healthy life. The catch is that health is a moving target. It’s a challenge that changes as people ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

A recipient of the 2025 Elite Trial Lawyers Lifetime Achievement Award, Morgan & Morgan's John Yanchunis spoke with the National Law Journal about his storied career, from bringing one of the nation’s ...

Healthcare professionals are calling for a fundamental shift in public perception around medically supervised weight loss ...

At the intersection of aesthetics and science, RegenCen is changing how patients think about aging. Born from a fusion of ...

Kenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 ...

I have lost 3st (19kg) in six months with Mounjaro injections, but I've noticed my hair is getting much thinner. Is there ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Navvi, the cash‑pay digital prescribing platform founded by physicians, today announced the launch of its All‑Specialty Compound Medication Marketplace and a formal call for additional accredited ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Wraparound care for patients taking GLP-1 agonists must include assessment of nutritional status to identify the risk of malnutrition, writes Ellen Fallows Food insecurity is increasing, particularly ...